Disease details

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

6 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03567057 (ClinicalTrials.gov)	July 18, 2018	22/5/2018	A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment	A Multicenter, Open-Label Safety and Efficacy Study of ADS-5102 Amantadine Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment	Multiple Sclerosis;Walking Impairment	Drug: ADS-5102, 274 mg	Adamas Pharmaceuticals, Inc.	NULL	Completed	18 Years	70 Years	All	424	Phase 3	United States;Canada
2	NCT03436199 (ClinicalTrials.gov)	March 29, 2018	12/2/2018	Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment	A 3-arm, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ADS-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking Impairment	Walking Impairment;Multiple Sclerosis	Drug: ADS-5102, 137 mg;Drug: ADS-5102, 274 mg;Other: Placebo	Adamas Pharmaceuticals, Inc.	NULL	Completed	18 Years	70 Years	All	558	Phase 3	United States;Canada
3	NCT03185065 (ClinicalTrials.gov)	October 4, 2017	9/6/2017	Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis	Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis	Fatigue in Multiple Sclerosis	Drug: Amantadine;Drug: Modafinil;Drug: Methylphenidate;Drug: Placebos	Johns Hopkins University	Patient-Centered Outcomes Research Institute	Completed	18 Years	N/A	All	141	Phase 3	United States
4	NCT02471222 (ClinicalTrials.gov)	May 2015	11/6/2015	Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment	Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment	Walking Impairment;Multiple Sclerosis	Drug: ADS-5102;Other: Placebo	Adamas Pharmaceuticals, Inc.	NULL	Completed	18 Years	70 Years	All	60	Phase 2	United States
5	EUCTR2012-003418-15-AT (EUCTR)	23/10/2012	09/11/2012	Methylphenidate modified release as treatment of MS-associated fatigue.	Methylphenidate modified release as treatment option of MS-associated fatigue. A single-center randomized double-blind placebo-controlled trial.	Fatigue is a very common symptom in multiple sclerosis. Its management comprises nonpharmacologic approaches like exercise, cooling procedures and energy conservation programs and as second step pharmacologic therapy. Until now, Amantadine, Modafinil or antidepressants have been used off-label among others, with some success. Until now, methylphenidate has been successfully used to treat fatigue in HIVand parkinson´s disease, data on its efficacy in MS are not available.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Ritalin LA 20mg capsules Product Name: Methylphenidate modified release 20 mg INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE Trade Name: Ritalin LA 30mg capsules Product Name: Methylphenidate modified release 30 mg INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE Trade Name: Ritalin LA 40mg capsules Product Name: Methylphenidate modified release 40 mg INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE	Medizinische Universität Wien	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Austria
6	EUCTR2010-023678-38-IT (EUCTR)	20/04/2011	02/02/2011	High-field structural and functional MRI to investigate the substrates of fatigue in multiple sclerosis and to monitor the effect of tailored treatments.Pharmacological substudy. - ND	High-field structural and functional MRI to investigate the substrates of fatigue in multiple sclerosis and to monitor the effect of tailored treatments.Pharmacological substudy. - ND	patients with multiple sclerosis MedDRA version: 9.1;Level: PT;Classification code 10028245	Trade Name: MANTADAN*20CPR 100MG INN or Proposed INN: Amantadine Trade Name: AMPYRA INN or Proposed INN: Ampyra	FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR	NULL	Not Recruiting			Female: yes Male: yes			Italy

先頭へ